Shanghai Kehua Bio-Engineering Co.,Ltd (SHE:002022)

Market Cap	2.99B
Revenue (ttm)	1.70B
Net Income (ttm)	-665.04M
Shares Out	500.62M
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,397,500
Average Volume	11,524,653
Open	6.02
Previous Close	5.95
Day's Range	5.95 - 6.07
52-Week Range	4.88 - 7.40
Beta	0.62
RSI	55.31
Earnings Date	Aug 29, 2025

About SHE:002022

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; automatic modular and clinical chemistry analyzer; automatic chemiluminescence immunoassay analyzers; and CLIA reagents tests. The c...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1981
• Employees: 2,033
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002022

Financial Performance

In 2024, SHE:002022's revenue was 1.76 billion, a decrease of -27.55% compared to the previous year's 2.43 billion. Losses were -640.60 million, 173.7% more than in 2023.